The Unites States Food and Drugs Administration has approved the first non-hormonal drug to treat hot flashes associated with menopause. The U.S. Food and Drugs Administration has approved the first non-hormonal drug to treat hot flashes associated with menopause. The drug, Brisdelle ( paroxetine ), contains the selective serotonin reuptake inhibitor paroxetine mesylate and can be used to treat moderate to severe hot flashes experience by women during menopause. Hot flashes during menopause are known to affect 75 percent of women worldwide. According to a FDA press release , though this condition is not fatal it can carry on for five or more years in some women causing a lot of discomfort and disrupted sleep. "There are a significant number of women who suffer from hot flashes associated with menopause and who cannot or do not want to use hormonal treatments," said Hylton V. Joffe, M.D., M.M.Sc., director of the Division of Bone, Reproductive and Urologic Products in the F